Literature DB >> 26076949

Epidemiology of venous thromboembolism.

John A Heit1.   

Abstract

Thrombosis can affect any venous circulation. Venous thromboembolism (VTE) includes deep-vein thrombosis of the leg or pelvis, and its complication, pulmonary embolism. VTE is a fairly common disease, particularly in older age, and is associated with reduced survival, substantial health-care costs, and a high rate of recurrence. VTE is a complex (multifactorial) disease, involving interactions between acquired or inherited predispositions to thrombosis and various risk factors. Major risk factors for incident VTE include hospitalization for surgery or acute illness, active cancer, neurological disease with leg paresis, nursing-home confinement, trauma or fracture, superficial vein thrombosis, and-in women-pregnancy and puerperium, oral contraception, and hormone therapy. Although independent risk factors for incident VTE and predictors of VTE recurrence have been identified, and effective primary and secondary prophylaxis is available, the occurrence of VTE seems to be fairly constant, or even increasing.

Entities:  

Mesh:

Year:  2015        PMID: 26076949      PMCID: PMC4624298          DOI: 10.1038/nrcardio.2015.83

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  271 in total

1.  Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.

Authors:  G Agnelli; P Prandoni; M G Santamaria; P Bagatella; A Iorio; M Bazzan; M Moia; G Guazzaloca; A Bertoldi; C Tomasi; G Scannapieco; W Ageno
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

2.  The genetics of haemostasis: a twin study.

Authors:  M de Lange; H Snieder; R A Ariëns; T D Spector; P J Grant
Journal:  Lancet       Date:  2001-01-13       Impact factor: 79.321

3.  Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

Authors:  M Zangari; E Anaissie; B Barlogie; A Badros; R Desikan; A V Gopal; C Morris; A Toor; E Siegel; L Fink; G Tricot
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

4.  Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis.

Authors:  L Pinede; J Ninet; P Duhaut; S Chabaud; S Demolombe-Rague; I Durieu; P Nony; C Sanson; J P Boissel
Journal:  Circulation       Date:  2001-05-22       Impact factor: 29.690

5.  Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial.

Authors:  J Merrer; B De Jonghe; F Golliot; J Y Lefrant; B Raffy; E Barre; J P Rigaud; D Casciani; B Misset; C Bosquet; H Outin; C Brun-Buisson; G Nitenberg
Journal:  JAMA       Date:  2001-08-08       Impact factor: 56.272

6.  An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study.

Authors:  M M Samama
Journal:  Arch Intern Med       Date:  2000 Dec 11-25

7.  Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy.

Authors:  J D Douketis; G A Foster; M A Crowther; M H Prins; J S Ginsberg
Journal:  Arch Intern Med       Date:  2000 Dec 11-25

8.  Use of statins and the subsequent development of deep vein thrombosis.

Authors:  J G Ray; M Mamdani; R T Tsuyuki; D R Anderson; E L Yeo; A Laupacis
Journal:  Arch Intern Med       Date:  2001-06-11

9.  Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis?

Authors:  J D Douketis; M A Crowther; G A Foster; J S Ginsberg
Journal:  Am J Med       Date:  2001-05       Impact factor: 4.965

10.  Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study.

Authors:  D R Danilenko-Dixon; J A Heit; M D Silverstein; B P Yawn; T M Petterson; C M Lohse; L J Melton
Journal:  Am J Obstet Gynecol       Date:  2001-01       Impact factor: 8.661

View more
  196 in total

1.  Assessment of warfarin algorithms for hospitalized adults: searching for a safe dosing strategy.

Authors:  Jessica L Cohen; Elena Thompson; Liron Sinvani; Andrzej Kozikowski; Guang Qiu; Renee Pekmezaris; Alex C Spyropoulos; Jason J Wang
Journal:  J Thromb Thrombolysis       Date:  2019-11       Impact factor: 2.300

2.  Prevalence of factor V leiden, MTHFR C677T and MTHFR A1298C polymorphisms in patients with deep vein thrombosis in Central Iran.

Authors:  Majid Ehsani; Aida Imani; Alireza Moravveji
Journal:  Mol Biol Rep       Date:  2018-05-31       Impact factor: 2.316

3.  Prediction Model for the Presence of Complications at Admission to Rehabilitation After Traumatic Spinal Cord Injury.

Authors:  Giorgio Scivoletto; Monica Torre; Marco Iosa; Maria Rosaria Porto; Marco Molinari
Journal:  Top Spinal Cord Inj Rehabil       Date:  2017-11-17

Review 4.  Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.

Authors:  Lindsay Robertson; James Strachan
Journal:  Cochrane Database Syst Rev       Date:  2017-02-14

5.  Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study.

Authors:  Hisham Badreldin
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

6.  Pre-Operative, Intra-Operative, and Post-Operative Factors Associated with Post-Discharge Venous Thromboembolism Following Colorectal Cancer Resection.

Authors:  Cary Jo R Schlick; Jessica Y Liu; Anthony D Yang; David J Bentrem; Karl Y Bilimoria; Ryan P Merkow
Journal:  J Gastrointest Surg       Date:  2019-08-16       Impact factor: 3.452

7.  Platelet function as a risk factor for venous thromboembolism in the Framingham Heart Study.

Authors:  Marja K Puurunen; Shih-Jen Hwang; Chris J O'Donnell; Geoffrey Tofler; Andrew D Johnson
Journal:  Thromb Res       Date:  2017-01-25       Impact factor: 3.944

8.  Sauna bathing reduces the risk of venous thromboembolism: a prospective cohort study.

Authors:  Setor K Kunutsor; Timo H Mäkikallio; Hassan Khan; Tanjaniina Laukkanen; Jussi Kauhanen; Jari A Laukkanen
Journal:  Eur J Epidemiol       Date:  2019-08-01       Impact factor: 8.082

9.  Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice.

Authors:  Konstantin Stark; Vanessa Philippi; Sven Stockhausen; Johanna Busse; Antonella Antonelli; Meike Miller; Irene Schubert; Parandis Hoseinpour; Sue Chandraratne; Marie-Luise von Brühl; Florian Gaertner; Michael Lorenz; Alessandra Agresti; Raffaele Coletti; Daniel J Antoine; Ralf Heermann; Kirsten Jung; Sven Reese; Iina Laitinen; Markus Schwaiger; Axel Walch; Markus Sperandio; Peter P Nawroth; Christoph Reinhardt; Sven Jäckel; Marco E Bianchi; Steffen Massberg
Journal:  Blood       Date:  2016-08-29       Impact factor: 22.113

10.  Thrombin generation profile in non-thrombotic factor V Leiden carriers.

Authors:  Paul Billoir; Thomas Duflot; Marielle Fresel; Marie Hélène Chrétien; Virginie Barbay; Véronique Le Cam Duchez
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.